An opposing role for IGF-1 in the CNS was the subject of a recent review underscoring that in AD, reducing IGF-1 signaling may serve to clear protein plaques and slow disease progression while at the same time reduced IGF-1 levels may lead to dysregulated cognition and neurovascular function47. The gene discussed is IGF1; the disease is Alzheimer disease.